Comparison of differences in immune cells and immune microenvironment among different kinds of oncolytic virus treatments DOI Creative Commons

Xiaoke Wu,

Shaokuan Fang

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 11, 2024

Oncolytic viruses are either naturally occurring or genetically engineered that can activate immune cells and selectively replicate in destroy cancer without damaging healthy tissues. virus therapy (OVT) represents an emerging treatment approach for cancer. In this review, we outline the properties of oncolytic then offer overview tumor microenvironment (TME) across various OVTs. A thorough understanding immunological mechanisms involved OVTs could lead to identification novel more effective therapeutic targets treatment.

Language: Английский

CLINICAL DEVELOPMENT OF IMMUNO-ONCOLOGY THERAPEUTICS DOI Creative Commons
Jianxin Wang, Qi Chen, Qi Shan

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217616 - 217616

Published: March 1, 2025

Language: Английский

Citations

1
Anticancer therapy-induced peripheral neuropathy in solid tumors: diagnosis, mechanisms, and treatment strategies DOI
Jiahong Jiang, Luna Jia Zhan, Bo Jiang

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217679 - 217679

Published: March 1, 2025

Language: Английский

Citations

1
Recent Advances in Biomimetic Strategies for the Immunotherapy of Glioblastoma DOI

Haoyu You,

Shuo Geng,

Shangkuo Li

et al.

Biomaterials, Journal Year: 2024, Volume and Issue: 311, P. 122694 - 122694

Published: June 28, 2024

Language: Английский

Citations

8
Current state of cancer immunity cycle: new strategies and challenges of using precision hydrogels to treat breast cancer DOI Creative Commons
Yan Zhu, Yanlin Su, Yaxin Guo

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 7, 2025

The cancer-immunity cycle provides a framework for series of events in anti-cancer immune responses, initiated by T cell-mediated tumor cell killing, which leads to antigen presentation and stimulation. Current immunomodulatory therapies breast cancer are often associated with short duration, poor targeting sites action, severe side effects. Hydrogels, their extracellular matrix-mimicking properties, tunable characteristics, diverse bioactivities, have garnered significant attention ability locally deliver immunomodulators cells, providing an microenvironment recruit, activate, expand host cells. This review focuses on the design considerations hydrogel platforms, including polymer backbone, crosslinking mechanisms, physicochemical components. effects therapeutic outcomes various systems treatment tissue regeneration highlighted, encompassing depots immunomodulator delivery, scaffolds hydrogels dependent inherent material properties. Finally, challenges that persist current future directions discussed.

Language: Английский

Citations

0
Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1/2 trial DOI Creative Commons
Zhichao Tan,

Yan Sheng Wu,

Zhengfu Fan

et al.

Journal for ImmunoTherapy of Cancer, Journal Year: 2025, Volume and Issue: 13(1), P. e010543 - e010543

Published: Jan. 1, 2025

Background Intratumoral oncolytic herpes simplex virus 2-GM CSF (OH2) injection has shown safety and antitumor efficacy in patients with solid tumors. Here, we examined the of OH2 as a single agent or combination HX008, an NMPA-approved PD-1 inhibitor, locally advanced metastatic sarcoma patients. Methods This multicenter, phase 1/2 trial enrolled injectable lesions, who had failed at least 1 more lines standard treatment. Patients were treated three dose levels (10 6 , 10 7 8 CCID 50 /mL) fixed HX008. The primary endpoints tolerability objective response rate determined by RECIST (V.1.1) criteria immune-RECIST 2. Results Between October 20, 2020 December 30, 2023, 26 enrolled. Seven single-agent 19 HX008 combination. No dose-limiting toxicities observed during escalation. We documented four partial complete responses injected one non-injected which all from group. Hence, overall was 0% 16.7% groups, respectively. duration 3.9–6.5 months. most frequent treatment-related adverse events (TRAEs) fever (n=9). Grade 3 4 TRAEs reported (15.4%). A clear increase CD8+cell density tumor microenvironment patients’ post-treatment specimens compared baseline. Conclusions is well tolerable sarcoma. Further investigation select subtypes warranted.

Language: Английский

Citations

0
Tuning Cellular Metabolism for Cancer Virotherapy DOI

Dian Xiong,

Qing Wang, Weiming Wang

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: 592, P. 216924 - 216924

Published: May 7, 2024

Language: Английский

Citations

2
Oncolytic virotherapy against lung cancer: key receptors and signaling pathways of viral entry DOI Creative Commons

Wenxun Dong,

Ying Luo, Daqian He

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 4, 2024

Lung cancer accounts for the highest cancer-related mortality worldwide. While immunotherapies targeting anti-tumor immune responses have demonstrated efficacy in clinical practice, demand novel treatment modalities remains urgent. Oncolytic viruses (OVs), which selectively kill tumor cells while stimulating an response, represent a potential breakthrough lung therapy. The induction of immunity by OVs is central to their overall therapeutic effectiveness. Many natural receptors on surface are dysregulated, providing entry points OVs. Furthermore, inherent dysregulation some key signaling pathways promotes proliferation, progression and metastasis, may facilitate selective viral replication. In this review, we explore application analyzing several major corresponding receptors. Then, also examine molecules with synergize modulating microenvironment. Finally, discuss combination administration strategies that warrant further trials validation. Despite certain limitations, tolerability positions virotherapy as promising avenue future treatment.

Language: Английский

Citations

1
Oncolytic vaccinia virus armed with 4–1BBL elicits potent and safe antitumor immunity and enhances the therapeutic efficiency of PD-1/PD-L1 blockade in a pancreatic cancer model DOI Creative Commons

Yushi Ju,

Feiyu Dai,

Yirong Wang

et al.

Translational Oncology, Journal Year: 2024, Volume and Issue: 50, P. 102151 - 102151

Published: Oct. 9, 2024

Language: Английский

Citations

1
Challenges and strategies toward oncolytic virotherapy for leptomeningeal metastasis DOI Creative Commons

Jiali Zhao,

Bi-Lin Lin,

Chen Luo

et al.

Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: Nov. 5, 2024

Meningeal metastasis (LM) is commonly seen in the advanced stages of cancer patients, often leading to a rapid decline survival time and quality life. Currently, there still lack standardized treatments. Oncolytic viruses (OVs) are class emerging therapeutics with advantages selectively replicating cells, delivering various eukaryotic transgenes, inducing immunogenic cell death, promoting anti-tumor immunity. Some studies applying OVs intrathoracically or intraperitoneally for treatment malignant pleural peritoneal effusions have shown promising therapeutic effects. If could be applied treat LM, it would bring significant benefits patients LM. In this review, we analyzed past research on use meningeal metastasis, summarized efficacy safety demonstrated by results, feasibility oncolytic virus therapy metastasis. We also existing data provide guidance development that can injected into cerebrospinal fluid (CSF).

Language: Английский

Citations

1
Light‐Enhanced Tandem‐Responsive Nano Delivery Platform for Amplified Anti‐tumor Efficiency DOI
Xing Wang, Yuanhang Li, Zhengjian Qi

et al.

Chemistry - An Asian Journal, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 16, 2024

Abstract Designing nanomedicines with low toxicity, high targeting, excellent therapeutic effects, and precise release is always the major challenges in clinical cancer treatment. Here, we report a light‐enhanced tandem‐responsive nano delivery platform COF‐B@X‐03 for amplified anti‐tumor efficiency. Biotin‐loaded could precisely target tumor cells, azo hydrazone bonds it would be depolymerized by overexpressed azoreductase acidic microenvironment hypoxic tumors. In vitro experimental results indicate mitochondrial endoplasmic reticulum stress caused under light direct cause of cell death. vivo data prove achieves oxygen dependent phototherapy, maintenance intratumoral hypoxia provides possibility continuous degradation to generate more reactive species photodynamic therapy released X‐03. end, phototherapy group higher inhibition rate than X‐03 group, which 81.37 %. Meanwhile, significantly eliminates risk metastasis. summary, construction this new direction achieving efficient removal solid tumors practice.

Language: Английский

Citations

0